TY - JOUR
T1 - Levosimendan for postoperative subclinical heart failure after noncardiac surgery
T2 - a randomized, double-blinded, phase III trial
AU - Reiterer, Christian
AU - Kabon, Barbara
AU - Taschner, Alexander
AU - Graf, Alexandra
AU - Adamowitsch, Nikolas
AU - Horvath, Katharina
AU - Emler, David
AU - Zotti, Oliver
AU - Hantakova, Nicole
AU - Hochreiter, Beatrix
AU - Fraunschiel, Melanie
AU - Clement, Theresa
AU - Fleischmann, Edith
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/12
Y1 - 2025/12
N2 - The effect of Levosimendan on postoperative natriuretic peptides in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative N-terminal brain pro natriuretic peptide (NT-proBNP) concentrations. In this prospective, double-blinded, parallel group, placebo-controlled, phase III trial 115 patients were assigned to perioperative single-dose of 12.5 mg of levosimendan and 115 to placebo between October 2020 through November 2023 (clinicaltrials.gov: NCT04329624). The primary outcome was postoperative maximum NT-proBNP concentration within the first 3 postoperative days. 228 patients completed the trial. Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: -64.51 ng.L-1; 95% CI -332.66 to 195.56; p = 0.61). Here, we show that perioperative levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP after noncardiac surgery.
AB - The effect of Levosimendan on postoperative natriuretic peptides in noncardiac surgical patients remains unknown. Thus, this study evaluates the effect of a perioperative levosimendan administration on postoperative N-terminal brain pro natriuretic peptide (NT-proBNP) concentrations. In this prospective, double-blinded, parallel group, placebo-controlled, phase III trial 115 patients were assigned to perioperative single-dose of 12.5 mg of levosimendan and 115 to placebo between October 2020 through November 2023 (clinicaltrials.gov: NCT04329624). The primary outcome was postoperative maximum NT-proBNP concentration within the first 3 postoperative days. 228 patients completed the trial. Postoperative maximum NT-proBNP concentrations did not differ significantly between the groups (effect estimate: -64.51 ng.L-1; 95% CI -332.66 to 195.56; p = 0.61). Here, we show that perioperative levosimendan administration did not lead to a significantly lower release in postoperative NT-proBNP after noncardiac surgery.
KW - Humans
KW - Simendan/therapeutic use
KW - Male
KW - Natriuretic Peptide, Brain/blood
KW - Female
KW - Double-Blind Method
KW - Aged
KW - Heart Failure/drug therapy
KW - Middle Aged
KW - Peptide Fragments/blood
KW - Postoperative Complications/drug therapy
KW - Prospective Studies
KW - Cardiotonic Agents/therapeutic use
UR - https://www.scopus.com/pages/publications/105009745932
U2 - 10.1038/s41467-025-60601-y
DO - 10.1038/s41467-025-60601-y
M3 - Journal article
C2 - 40593481
SN - 2041-1723
VL - 16
SP - 5847
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5847
ER -